Strong Financial Performance
Danaher Corporation delivered third quarter sales of $6.1 billion and a 3% core revenue growth. The adjusted diluted net earnings per common share were up approximately 10% year-over-year at $1.89.
Bioprocessing Business Momentum
The bioprocessing segment saw high single-digit growth in core revenue, driven by robust demand for commercialized therapies at large pharma and CDMO customers.
Successful New Product Launches
Danaher launched several leading-edge products and technologies, including Cytiva's ÄKTA readyflux TFF system 500 and Beckman Coulter's Access and BD-tau assay.
Share Repurchase Program
Danaher deployed approximately $2 billion towards the repurchase of 10 million shares and approved a new program authorizing the purchase of up to 35 million additional shares.